The persistence of seizures after tumor resection negatively affects survival in low-grade glioma patients: a clinical retrospective study.
Awake craniotomy
Engel class
Epilepsy
Extent of resection
Low-grade glioma
Journal
Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161
Informations de publication
Date de publication:
May 2022
May 2022
Historique:
received:
27
07
2021
accepted:
10
10
2021
revised:
09
10
2021
pubmed:
26
10
2021
medline:
23
4
2022
entrez:
25
10
2021
Statut:
ppublish
Résumé
Seizures are the most common clinical manifestation of low-grade glioma (LGG). Many papers hypothesized an influence of epilepsy on glioma progression. To our knowledge, no clinical study demonstrated a direct relationship between persistence of epileptic seizures after surgery and overall survival (OS) in LGG patients. The present study aims at investigating the correlation between post-operative seizure outcome and survival in tumor-related epilepsy (TRE) patients. We performed a retrospective analysis of adult patients affected by TRE who underwent surgery for resection of LGG in a single high-volume neurosurgical center. Seizure outcome was assessed 1 year after surgery and categorized according to Engel classification. Clinical, molecular and radiological features were evaluated in univariate and multivariate analyses to investigate the correlation with OS. A total of 146 patients met the inclusion criteria. Histopathological diagnosis was Diffuse Astrocytoma isocitrate dehydrogenase (IDH) wild type in 16 patients (11%), Diffuse astrocytoma IDH mutated in 89 patients (61%) and oligodendroglioma IDH mutated, 1p 19q codeleted in 41 patients (28%). 1 year after surgery, 103 (70.6%) patients were in Engel class 1. Median duration of follow-up period was 69.5 months. Median OS was 79.3 (72.2-86.4) months in the whole population, while it was 86.8 (78.4-95.2), 63.9 (45.7-82), 63.7 (45.2-82.2) and 47.5 (18.3-76.6) months for patients in Engel class 1, 2, 3 and 4, respectively. In a univariate analysis, Engel class evaluated 1 year after surgery significantly influenced OS (p < 0.01). Multivariate analysis showed that OS was independently associated with extent of resection (p = 0.02), molecular class (p < 0.01) and Engel class (p = 0.04). Seizure control 1 year after surgery significantly predicted survival of patients affected by LGG-related epilepsy in a large monocentric retrospective series. Future studies are needed to confirm these results and to assess if an epilepsy-surgical therapeutic approach may improve OS.
Identifiants
pubmed: 34693462
doi: 10.1007/s00415-021-10845-7
pii: 10.1007/s00415-021-10845-7
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2627-2633Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.
Références
Duffau H (2017) Diffuse low-grade gliomas in adults, 2nd edn. Springer, London
doi: 10.1007/978-3-319-55466-2
Pallud J, Audureau E, Blonski M, Sanai N, Bauchet L, Fontaine D, Mandonnet E, Dezamis E, Psimaras D, Guyotat J, Peruzzi P, Page P, Gal B, Parraga E, Baron MH, Vlaicu M, Guillevin R, Devaux B, Duffau H, Taillandier L, Capelle L, Huberfeld G (2014) Epileptic seizures in diffuse low-grade gliomas in adults. Brain 137:449–462. https://doi.org/10.1093/brain/awt345
doi: 10.1093/brain/awt345
Duffau H (2018) Diffuse low-grade glioma, oncological outcome and quality of life: a surgical perspective. Curr Opin Oncol 30:383–389. https://doi.org/10.1097/CCO.0000000000000483
doi: 10.1097/CCO.0000000000000483
Berger MS, Deliganis AV, Dobbins J, Keles GE (1994) The effect of extent of resection on recurrence in patients with low grade cerebral hemisphere gliomas. Cancer 74:1784–1791. https://doi.org/10.1002/1097-0142(19940915)74:6%3c1784::aid-cncr2820740622%3e3.0.co;2-d
doi: 10.1002/1097-0142(19940915)74:6<1784::aid-cncr2820740622>3.0.co;2-d
Ius T, Isola M, Budai R, Pauletto G, Tomasino B, Fadiga L, Skrap M (2012) Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and its impact on overall survival. A single-institution experience in 190 patients. J Neurosurg 117:1039–1052. https://doi.org/10.3171/2012.8.jns12393
doi: 10.3171/2012.8.jns12393
Ius T, Pauletto G, Isola M, Gregoraci G, Budai R, Lettieri C, Eleopra R, Fadiga L, Skrap M (2014) Surgery for insular low-grade glioma: predictors of postoperative seizure outcome. J Neurosurg 120:12–23
doi: 10.3171/2013.9.JNS13728
Ius T, Pauletto G, Tomasino B, Maieron M, Budai R, Isola M, Cesselli D, Lettieri C, Skrap M (2020) Predictors of postoperative seizure outcome in low grade glioma: from volumetric analysis to molecular stratification. Cancers. https://doi.org/10.3390/cancers12020397
doi: 10.3390/cancers12020397
Kerkhof M, Vecht CJ (2013) Seizure characteristics and prognostic factors of gliomas. Epilepsia 54(Suppl 9):12–17. https://doi.org/10.1111/epi.12437
doi: 10.1111/epi.12437
Englot DJ, Han SJ, Berger MS, Barbaro NM, Chang EF (2012) Extent of surgical resection predicts seizure freedom in low-grade temporal lobe brain tumors. Neurosurgery 70:921–928. https://doi.org/10.1227/NEU.0b013e31823c3a30 (Discussion 928)
doi: 10.1227/NEU.0b013e31823c3a30
Huberfeld G, Vecht CJ (2016) Seizures and gliomas–towards a single therapeutic approach. Nat Rev Neurol 12:204–216
doi: 10.1038/nrneurol.2016.26
Berntsson SG, Malmer B, Bondy ML, Qu M, Smits A (2009) Tumor-associated epilepsy and glioma: are there common genetic pathways? Acta Oncol 48:955–963. https://doi.org/10.1080/02841860903104145
doi: 10.1080/02841860903104145
Koekkoek JAF, Kerkhof M, Dirven L, Heimans JJ, Reijneveld JC, Taphoorn MJB (2015) Seizure outcome after radiotherapy and chemotherapy in low-grade glioma patients: a systematic review. Neuro Oncol 17:924–934
doi: 10.1093/neuonc/nov032
Sherman JH, Moldovan K, Yeoh HK, Starke RM, Pouratian N, Shaffrey ME, Schiff D (2011) Impact of temozolomide chemotherapy on seizure frequency in patients with low-grade gliomas. J Neurosurg 114:1617–1621. https://doi.org/10.3171/2010.12.JNS101602
doi: 10.3171/2010.12.JNS101602
Louis D, Ohgaki H, Wiestler O, Cavenee W (2016) World Health Organization histological classification of tumours of the central nervous system. France
Fisher RS, Cross JH, French JA, Higurashi N, Hirsch E, Jansen FE, Lagae L, Moshe SL, Peltola J, Roulet Perez E, Scheffer IE, Zuberi SM (2017) Operational classification of seizure types by the International League Against Epilepsy: Position Paper of the ILAE Commission for Classification and Terminology. Epilepsia 58:522–530. https://doi.org/10.1111/epi.13670
doi: 10.1111/epi.13670
Engel J (1993) Surgical Treatment of Epilepsies. Editor. Raven Preess,
Ius T, Ciani Y, Ruaro ME, Isola M, Sorrentino M, Bulfoni M, Candotti V, Correcig C, Bourkoula E, Manini I, Pegolo E, Mangoni D, Marzinotto S, Radovic S, Toffoletto B, Caponnetto F, Zanello A, Mariuzzi L, Di Loreto C, Beltrami AP, Piazza S, Skrap M, Cesselli D (2017) An NF-κB signature predicts low-grade glioma prognosis: a precision medicine approach based on patient-derived stem cells. Neuro Oncol 20:776–787. https://doi.org/10.1093/neuonc/nox234
doi: 10.1093/neuonc/nox234
Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW (2016) The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 131:803–820. https://doi.org/10.1007/s00401-016-1545-1
doi: 10.1007/s00401-016-1545-1
Cesselli D, Ius T, Isola M, Del Ben F, Da Col G, Bulfoni M, Turetta M, Pegolo E, Marzinotto S, Scott CA, Mariuzzi L, Di Loreto C, Beltrami AP, Skrap M (2019) Application of an artificial intelligence algorithm to prognostically stratify grade II gliomas. Cancers. https://doi.org/10.3390/cancers12010050
doi: 10.3390/cancers12010050
Shan X, Fan X, Liu X, Zhao Z, Wang Y, Jiang T (2018) Clinical characteristics associated with postoperative seizure control in adult low-grade gliomas: a systematic review and meta-analysis. Neuro Oncol 20:324–331. https://doi.org/10.1093/neuonc/nox130
doi: 10.1093/neuonc/nox130
Still MEH, Roux A, Huberfeld G, Bauchet L, Baron MH, Fontaine D, Blonski M, Mandonnet E, Guillevin R, Guyotat J, Taillandier L, Capelle L, Duffau H, Pallud J (2019) Extent of Resection and residual tumor thresholds for postoperative total seizure freedom in epileptic adult patients harboring a supratentorial diffuse low-grade glioma. Neurosurgery 85:E332–E340. https://doi.org/10.1093/neuros/nyy481
doi: 10.1093/neuros/nyy481
Liu Z, Wang Y, Liu X, Du Y, Tang Z, Wang K, Wei J, Dong D, Zang Y, Dai J, Jiang T, Tian J (2018) Radiomics analysis allows for precise prediction of epilepsy in patients with low-grade gliomas. NeuroImage Clin 19:271–278. https://doi.org/10.1016/j.nicl.2018.04.024
doi: 10.1016/j.nicl.2018.04.024
Zhong Z, Wang Z, Wang Y, You G, Jiang T (2015) IDH1/2 mutation is associated with seizure as an initial symptom in low-grade glioma: a report of 311 Chinese adult glioma patients. Epilepsy Res 109:100–105. https://doi.org/10.1016/j.eplepsyres.2014.09.012
doi: 10.1016/j.eplepsyres.2014.09.012
Wang Y, Tang K, Zhao J, Liu L, Feng J (2017) FOXO4 expression is associated with the occurrence and outcome of seizures: An RNA-sequencing analysis of low-grade gliomas. Seizure 52:41–45. https://doi.org/10.1016/j.seizure.2017.09.012
doi: 10.1016/j.seizure.2017.09.012
Santos-Pinheiro F, Park M, Liu D, Kwong LN, Cruz S, Levine NB, O’Brien BJ, Chen M (2019) Seizure burden pre- and postresection of low-grade gliomas as a predictor of tumor progression in low-grade gliomas. Neurooncol Pract 6:209–217. https://doi.org/10.1093/nop/npy022
doi: 10.1093/nop/npy022
Koekkoek JA, Dirven L, Taphoorn MJ (2017) The withdrawal of antiepileptic drugs in patients with low-grade and anaplastic glioma. Expert Rev Neurother 17:193–202. https://doi.org/10.1080/14737175.2016.1219250
doi: 10.1080/14737175.2016.1219250
Lim-Fat MJ, Wen PY (2020) Glioma progression through synaptic activity. Nat Rev Neurol 16:6–7. https://doi.org/10.1038/s41582-019-0290-1
doi: 10.1038/s41582-019-0290-1
Izumoto S, Miyauchi M, Tasaki T, Okuda T, Nakagawa N, Nakano N, Kato A, Fujita M (2018) Seizures and tumor progression in glioma patients with uncontrollable epilepsy treated with perampanel. Anticancer Res 38:4361–4366. https://doi.org/10.21873/anticanres.12737
doi: 10.21873/anticanres.12737
Yao PS, Zheng SF, Wang F, Kang DZ, Lin YX (2018) Surgery guided with intraoperative electrocorticography in patients with low-grade glioma and refractory seizures. J Neurosurg 128:840–845. https://doi.org/10.3171/2016.11.JNS161296
doi: 10.3171/2016.11.JNS161296
Kemerdere R, Yuksel O, Kacira T, Yeni N, Ozkara C, Tanriverdi T, Uzan M, Ozyurt E (2014) Low-grade temporal gliomas: surgical strategy and long-term seizure outcome. Clin Neurol Neurosurg 126:196–200. https://doi.org/10.1016/j.clineuro.2014.09.007
doi: 10.1016/j.clineuro.2014.09.007
Mazzucchi E, La Rocca G, Ius T, Sabatino G, Della Pepa GM (2020) Multimodality imaging techniques to assist surgery in low-grade gliomas. World Neurosurg 133:423–425. https://doi.org/10.1016/j.wneu.2019.10.120
doi: 10.1016/j.wneu.2019.10.120
Ius T, Mazzucchi E, Tomasino B, Pauletto G, Sabatino G, Della Pepa GM, La Rocca G, Battistella C, Olivi A, Skrap M (2021) Multimodal integrated approaches in low grade glioma surgery. Sci Rep 11:9964. https://doi.org/10.1038/s41598-021-87924-2
doi: 10.1038/s41598-021-87924-2
Skrap M, Marin D, Ius T, Fabbro F, Tomasino B (2016) Brain mapping: a novel intraoperative neuropsychological approach. J Neurosurg 125:877–887. https://doi.org/10.3171/2015.10.jns15740
doi: 10.3171/2015.10.jns15740
Di Carlo DT, Duffau H, Cagnazzo F, Benedetto N, Morganti R, Perrini P (2020) IDH wild-type WHO grade II diffuse low-grade gliomas. A heterogeneous family with different outcomes. Systematic review and meta-analysis. Neurosurg Rev 43:383–395. https://doi.org/10.1007/s10143-018-0996-3
doi: 10.1007/s10143-018-0996-3
Ius T, Ng S, Young JS, Tomasino B, Polano M, Ben-Israel D, Kelly JJP, Skrap M, Duffau H, Berger MS (2021) The benefit of early surgery on overall survival in incidental low grade glioma patients: a multicenter study. Neuro Oncol. https://doi.org/10.1093/neuonc/noab210
doi: 10.1093/neuonc/noab210